Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

BACKGROUND: Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the kidney. Clinical data describing the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Diabetol
Autors principals: Arow, M., Waldman, M., Yadin, D., Nudelman, V., Shainberg, A., Abraham, N. G., Freimark, D., Kornowski, R., Aravot, D., Hochhauser, E., Arad, M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6953156/
https://ncbi.nlm.nih.gov/pubmed/31924211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0980-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars